TEMODAL is an imidazotetrazine alkylating agent with antitumor activity. It undergoes rapid chemical conversion in the systemic circulation at physiologic pH to the active compound, MTIC (monomethyl triazeno imidazole carboxamide). The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position. Cytotoxic lesions that develop subsequently are thought to involve aberrant repair of the methyl adduct.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
